ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine against Zika virus infection

BACKGROUND: While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barré syndrome are well-described. There are no approved ZIKV vaccines. METHODS: ZIKA-001, a phase I, open label, clinical trial evaluated the safety and immunogenicity of synthetic, consen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Tebas, Pablo, Roberts, Christine C., Muthumani, Kar, Reuschel, Emma L., Kudchodkar, Sagar B., Zaidi, Faraz I., White, Scott, Khan, Amir S., Racine, Trina, Choi, Hyeree, Boyer, Jean, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Spruill, Susan E., Kobinger, Gary P., Weiner, David B., Maslow, Joel N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824915/
https://ncbi.nlm.nih.gov/pubmed/34525286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1708120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados